Pressure overload-induced cardiac remodeling and dysfunction in the absence of interleukin 6 in mice

Laboratory Investigation

Volumn 92, Issue 11, 2012, Pages 1518-1526

  Lai, N Chin ^a   Gao, Mei Hua ^a   Tang, Eric ^a   Tang, Ruoying ^a   Guo, Tracy ^a   Dalton, Nancy D ^a   Deng, Aihua ^a   Tang, Tong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

fibrosis; heart failure; hypertrophy; IL 6; inflammatory cytokine; LV function; pressure overload

Indexed keywords

INTERLEUKIN 11; INTERLEUKIN 6; SCLEROPROTEIN; STAT3 PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; APOPTOSIS; ARTICLE; ATTENUATION; AUTOPHAGY; AUTOPSY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HISTOLOGY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; AUTOPHAGY; FEMALE; FIBROSIS; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PRESSURE; STAT3 TRANSCRIPTION FACTOR; VENTRICULAR REMODELING;

EID: 84868553979     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.97     Document Type: Article

References (31)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.
2. Mann D. Pathophysiology of heart failure. In: Libby P, Bonow R, Mann D, Zipes D (eds). Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. Saunders: Philadelphia, 2008, pp 541-560.
3. Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev 2010;15:331-341.
4. Birner CM, Ulucan C, Fredersdorf S, et al. Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: superiority of BNP. Cytokine 2007;40:89-97. (Pubitemid 350180525)
5. Tsutamoto T, Asai S, Tanaka T, et al. Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure. Eur J Heart Fail 2007;9:1032-1037. (Pubitemid 47451817)
6. Hirota H, Izumi M, Hamaguchi T, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels 2004;19:237-241. (Pubitemid 39335083)
7. Zolk O, Ng LL, Brien RJ, et al. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 2002;106: 1442-1446.
8. Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 2010; 55:2129-2137.
9. Matsubara J, Sugiyama S, Nozaki T, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011; 57:861-869.
10. Kubota T, Miyagishima M, Alvarez RJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recentonset and end-stage congestive heart failure. J Heart Lung Transplant 2000;19:819-824.
11. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317-2322. (Pubitemid 37413536)
12. Fisman EZ, Benderly M, Esper RJ, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 2006;98:14-18. (Pubitemid 43902673)
13. Ohtsuka T, Hamada M, Inoue K, et al. Relation of circulating interleukin-6 to left ventricular remodeling in patients with reperfused anterior myocardial infarction. Clin Cardiol 2004;27:417-420. (Pubitemid 38849968)
14. Yan AT, Yan RT, Cushman M, et al. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J 2010;31:875-882.
15. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257: 387-389.
16. Villegas S, Villarreal FJ, Dillmann WH. Leukemia inhibitory factor and interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes. Basic Res Cardiol 2000;95:47-54. (Pubitemid 30150727)
17. Janssen SP, Gayan-Ramirez G, Van den Bergh A, et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005;111:996-1005. (Pubitemid 40354517)
18. Melendez GC, McLarty JL, Levick SP, et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010;56:225-231.
19. Coles B, Fielding CA, Rose-John S, et al. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol 2007;171:315-325. (Pubitemid 47339248)
20. Tang T, Lai NC, Hammond HK, et al. Adenylyl cyclase 6 deletion reduces LV hypertrophy, dilation, dysfunciton and fibrosis in pressureoverloaded female mice. J Am Coll Cardiol 2010;55:1476-1486.
21. Takahashi T, Tang T, Lai NC, et al. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation 2006;114:388-396. (Pubitemid 44264820)
22. Tamariz L, Hare JM. Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers. Eur Heart J 2010;31:768-770.
23. Kimura R, Maeda M, Arita A, et al. Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine. Cytokine 2007;38:107-115. (Pubitemid 47077909)
24. Obana M, Maeda M, Takeda K, et al. Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation 2010;121:684-691.
25. Matsushita K, Iwanaga S, Oda T, et al. Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest 2005;85:1210-1223. (Pubitemid 41348637)
26. Dawn B, Xuan YT, Guo Y, et al. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 2004;64:61-71. (Pubitemid 39208923)
27. Kurdi M, Booz GW. Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling. J Cardiovasc Pharmacol 2007; 50:126-141. (Pubitemid 47267738)
28. Lecour S, James RW. When are pro-inflammatory cytokines SAFE in heart failure? Eur Heart J 2011;32:680-685.
29. Gwechenberger M, Mendoza LH, Youker KA, et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999;99:546-551. (Pubitemid 29061871)
30. Ono K, Matsumori A, Shioi T, et al. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998;98:149-156. (Pubitemid 28317895)
31. Fuchs M, Hilfiker A, Kaminski K, et al. Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J 2003;17:2118-2120.